Our pipeline at a glance

Updated November 2, 2020. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Download Merck Pipeline PDF

Phase 2 12 Programs
  • Anti-Viral SARS-CoV-2 infection molnupiravir MK-44821
  • Chikungunya virus Vaccine V184
  • HIV-1 infection islatravir (MK-8591)
  • Schizophrenia MK-8189
  • Cutaneous squamous cell carcinoma V937
  • Breast cancer V937
  • Melanoma cancer V937
  • Colorectal cancer TUKYSA® (MK-7119) 1
  • Non-small cell lung cancer MK-76842
  • Melanoma MK-76842
  • Overgrowth syndrome MK-7075
  • Non-small cell lung cancer MK-58902
  • Non-small cell lung cancer MK-42802
  • Hematological malignancies MK-42802
  • Head and neck cancer MK-14542
  • Non-small cell lung cancer MK-13082
  • Melanoma MK-13082
  • Hematological malignancies MK-1026
  • Advanced solid tumors LYNPARZA® (MK-7339) 1, 3
  • Glioblastoma LENVIMA® (MK-7902) 1, 2
  • Gastric LENVIMA® (MK-7902) 1, 2
  • Colorectal LENVIMA® (MK-7902) 1, 2
  • Biliary Tract LENVIMA® (MK-7902) 1, 2
  • Advanced solid tumors LENVIMA® (MK-7902) 1, 2
  • breast cancer ladiratuzumab vedotin (MK-6440)1,3
  • Advanced solid tumors ladiratuzumab vedotin (MK-6440)1,3
  • Advanced solid tumors KEYTRUDA® (MK-3475)
  • HNSCC V937
  • Respiratory syncytial virus MK-1654
  • Pneumococcal V116
  • Cytomégalovirus vaccine V160
Phase 3 25 Programs
  • HIV-1 infection MK-8591A (doravirine/islatravir)
  • Esophageal Cancer KEYTRUDA® (MK-3475) (EU)
  • Cancer RCC MK-6482
  • Colorectal LYNPARZA® (MK-7339) 1, 2
  • Non-small cell lung cancer LYNPARZA® (MK-7339) 1, 2
  • Head & neck squamous cell carcinoma LENVIMA® (MK-7902) 1, 2
  • Non-small cell lung cancer LENVIMA® (MK-7902) 1, 2
  • Melanoma cancer LENVIMA® (MK-7902) 1, 2
  • Endometrial cancer LENVIMA® (MK-7902)1, 2 (EU)
  • Bladder cancer LENVIMA® (MK – 7902) 1, 2
  • Prostate cancer KEYTRUDA® (MK-3475)
  • Ovarian cancer KEYTRUDA® (MK-3475)
  • Breast cancer TUKYSA® (MK-7119) 1
  • Mesothelioma cancer KEYTRUDA® (MK-3475)
  • Biliary tract cancer KEYTRUDA® (MK-3475)
  • Small cell lung cancer KEYTRUDA® (MK-3475) (EU)
  • Liver cancer KEYTRUDA® (MK-3475) (EU)
  • Gastric cancer KEYTRUDA® (MK-3475) (EU)
  • Endometrial cancer KEYTRUDA® (MK-3475) (EU)
  • Cutaneous squamous cell carcinoma KEYTRUDA®
    (MK-3475) (EU)
  • Cervical cancer KEYTRUDA® (MK-3475) (EU)
  • Breast cancer KEYTRUDA® (MK-3475) (EU)
  • Nasopharyngeal cancer KEYTRUDA® (MK-3475)
  • Cough gefapixant (MK-7264)
  • Pneumoconjugate vaccine V114
Under review 3 Programs
  • Heart failure vericiguat (MK-1242)2 ( US,EU, JPN)
  • Bacterial infection-RECARBRIO™
    MK-7655A (JPN)
  • Pediatric neurofibromatosis type-1 KOSELUGO® (MK-5618)1 (EU)

Therapeutic Key Areas

  • 1 - Being developed in collaboration.
  • 2 - Being developed in combination with KEYTRUDA.
  • 3 - Being developed as a monotherapy and in combination with KEYTRUDA.

What do the phases of clinical trials mean?

Phase 1

Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always.  The trial often takes place in a hospital. The goals are to determine:

  • If the medicine or vaccine is safe
  • If there are any side effects
  • How the medicine is broken down by and discharged from the body
  • How much medicine is needed and how often
  • For a vaccine, researchers see if it causes the desired response from the body’s immune system

Phase 1 trials an take from six months to one year to complete.

Phase 2

Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:

  • How well the medicine or vaccine works
  • If the medicine or vaccine is safe
  • If there are any side effects
  • How much of the medicine or vaccine is needed and how often

Phase 2 trials can take from six months to one year or more to complete.

Phase 3

Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:

  • Confirm that the medication or vaccine is effective
  • Identify and monitor side effects
  • Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.

Under review

The application has been submitted to the regulatory authorities for review.

No Duty to Update

The information contained in this chart was current as of November 2, 2020. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after November 2, 2020.

The chart reflects the company research pipeline as of November 2, 2020.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.